<DOC>
	<DOC>NCT03055026</DOC>
	<brief_summary>Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo-controlled study.</brief_summary>
	<brief_title>Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Objective diagnosis of colorectal cancer; Elective laparoscopic surgery for colorectal cancer Whatever the stage of cancer Antithrombotic prophylaxis with LMWH administered for 7Â±2 days after surgery Age &lt; 18 years Surgery for noncancer disease Duration of surgery &lt; 45 min Conversion to open surgery Other indication for anticoagulant therapy Known cerebral metastases Kidney or liver failure Known hemorrhagic diathesis or high risk for bleeding History of intracerebral bleeding or neurosurgery within 6 months History of heparin induced thrombocytopenia Pregnancy or lactation Refusal of informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>